$VERA News
Last published 5d ago
- 5d agoVERAVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBRISBANE, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that, on November 2, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of
- 5d agoVERAVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...
- 6d agoVERAVera Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 6d agoVERAVera Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial ResultsGlobeNewswireTRUTAKNA® (atacicept-vymj) U.S. launch building early momentum following July 7 accelerated approval by the U.S. Food and Drug Administration (FDA) with approximately 700 Patient Start Forms (PSFs) to date and $10.3
- 1w agoVERAVera Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation ConferenceGlobeNewswireBRISBANE, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a commercial-stage biotechnology company, today announced that the Company’s management team will participate in a fireside
- 2w agoVERAVera Therapeutics - October 22 Investor Webcast - VERA THERAPEUTICS INCEarnings Call TranscriptsGood day, everyone. Welcome to the Vera Therapeutics October 22nd Investor Webcast. All participants will be in listen-only mode until the question-and-answer session begins. Following the presentation, we will conduct a
- 2w agoVERAVera Therapeutics - October 22 Investor Webcast - VERA THERAPEUTICS INCEarnings Call TranscriptsGood day, everyone. Welcome to the Vera Therapeutics October 22nd Investor Webcast. All participants will be in listen-only mode until the question-and-answer session begins. Following the presentation, we will conduct a
- 2w agoVERAVera Therapeutics - October 22 Investor Webcast - VERA THERAPEUTICS INCEarnings Call TranscriptsGood day, everyone. Welcome to the Vera Therapeutics October 22nd Investor Webcast. All participants will be in listen-only mode until the question-and-answer session begins. Following the presentation, we will conduct a
- 2w agoVERAVera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of MedicineGlobeNewswireTRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, achieved statistical significance in all prespecified endpoints, including eGFR change from baseline and annualized slope, and risk reduction in
- 3w agoVERAVera Therapeutics to Host ASN Kidney Week Investor Webcast and Third Quarter 2026 Financial Results Conference WebcastGlobeNewswireInvestor webcast at 4:30 p.m. ET on October 22 to discuss ORIGIN 3 final efficacy results for TRUTAKNA™ (atacicept-vymj) featured in a late-breaking oral presentation during the opening plenary session of ASN Kidney
- 1mo agoVERAMorgan Stanley 24th Annual Global Healthcare Conference - VERA THERAPEUTICS INCEarnings Call TranscriptsGreat. Good afternoon, everybody. Thanks for sticking around for our last Fireside today. We're really pleased to have Vera with us. I'm going to let Marshall make some introductory comments, and then we'll jump into Q&A
- 1mo agoVERAMorgan Stanley 24th Annual Global Healthcare Conference - VERA THERAPEUTICS INCEarnings Call TranscriptsGreat. Good afternoon, everybody. Thanks for sticking around for our last Fireside today. We're really pleased to have Vera with us. I'm going to let Marshall make some introductory comments, and then we'll jump into Q&A
- 1mo agoVERAvera - 1773634 - VERA THERAPEUTICS INCEarnings Call TranscriptsGreat. Good afternoon, everybody. Thanks for sticking around for our last Fireside today. We're really pleased to have Vera with us. I'm going to let Marshall make some introductory comments, and then we'll jump into Q&A
- 1mo agoVERAVera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA NephropathyGlobeNewswireTRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, met all prespecified endpoints, including unprecedented placebo-adjusted estimated glomerular filtration rate (eGFR) and composite kidney disease
- 2mo agoVERAVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBRISBANE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that, on September 1, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of
- 2mo agoVERAVera Therapeutics to Participate at Upcoming Investor ConferencesGlobeNewswireBRISBANE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a commercial-stage biotechnology company, today announced that the Company’s management team will present and participate in
- 3mo agoVERAVera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial ResultsGlobeNewswireTRUTAKNA™ granted accelerated approval by U.S. Food and Drug Administration (FDA) in adult patients with primary IgA nephropathy (IgAN) at risk for disease progression.Alignment with FDA on earlier ORIGIN 3 final
- 3mo agoVERAVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBRISBANE, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that, on August 3, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera
- 4mo agoVERAVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBRISBANE, Calif., July 10, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that, on July 6, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera
- 4mo agoVERAVera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William TurnerGlobeNewswireBRISBANE, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a commercial-stage biotechnology company, today announced a planned transition of the Chief Regulatory Officer position.
- 4mo agoVERAVera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA NephropathyGlobeNewswireTRUTAKNA is the first and only available therapy that binds both B-cell activating factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), addressing the immunological drivers at the source of IgA nephropathy
- 5mo agoVERAVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBRISBANE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that, on June 2, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera
- 5mo agoVERAVera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA NephropathyGlobeNewswirePrescription Drug User Fee Act (PDUFA) date of July 7, 2026 for Biologics License Application (BLA) for accelerated approval of atacicept in patients with IgA Nephropathy (IgAN)Revised ORIGIN 3 eGFR analysis now planned
- 6mo agoVERAVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBRISBANE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that, on May 4, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera
- 6mo agoVERAVera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial ResultsGlobeNewswireU.S. Food and Drug Administration (FDA) granted priority review to Biologics License Application (BLA) for the accelerated approval of atacicept in adult patients with IgA Nephropathy (IgAN) with a Prescription Drug User
- 6mo agoVERAVera Therapeutics to Participate in the Bank of America Securities 2026 Health Care ConferenceGlobeNewswireBRISBANE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious
- 7mo agoVERAVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBRISBANE, Calif., April 10, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that, on April 8, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera
- 7mo agoVERAVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBRISBANE, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that, on March 23, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera
- 7mo agoPCVXVERAVera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal OfficerGlobeNewswireBRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious
- 8mo agoVRTXVERAVertex passes key test In quest to treat kidney diseasesCNBCVertex Pharmaceuticals said its drug for a rare kidney condition succeeded in a Phase 3 trial.
- 8mo agoVERAVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBRISBANE, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that, on March 3, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera
- 8mo agoVERAVera Therapeutics Appoints Christopher Hite to Board of DirectorsGlobeNewswireBRISBANE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious
- 8mo agoVERAVera Therapeutics Provides Business Update and Reports Full Year 2025 Financial ResultsGlobeNewswirePositive Phase 3 data from ORIGIN 3 study of atacicept in IgA nephropathy (IgAN) presented at American Society of Nephrology (ASN) Kidney Week and published in the New England Journal of MedicineU.S. Food and Drug
- 8mo agoVERAVera Therapeutics to Participate at Upcoming Investor ConferencesGlobeNewswireBRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients
- 9mo agoVERAVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBRISBANE, Calif., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that, on February 2, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera
- 9mo agoVERAVera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial OfficerGlobeNewswireBRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients
- 10mo agoVERAVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBRISBANE, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that, on January 5, 2026, the Compensation Committee of the Board of Directors of Vera Therapeutics granted
- 10mo agoVERAVera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireBRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. ("Vera Therapeutics"), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for
- 10mo agoVERAVera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA NephropathyGlobeNewswireFDA assigned PDUFA target action date of July 7, 2026.If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN.Atacicept received FDA Breakthrough Therapy Designation for the
- 11mo agoVERAVera Therapeutics Announces Pricing of Public Offering of Class A Common StockGlobeNewswireBRISBANE, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. ("Vera Therapeutics"), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for
- 11mo agoVERAVera Therapeutics Announces Proposed Public Offering of Class A Common StockGlobeNewswireBRISBANE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. ("Vera Therapeutics"), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for
- 11mo agoVERAVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBRISBANE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that, on December 2, 2025, the Compensation Committee of the Board of Directors of Vera Therapeutics granted
- 11mo agoVERAVera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of DirectorsGlobeNewswireBRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients
- 11mo agoVERAVera Therapeutics to Participate at Upcoming Investor ConferencesGlobeNewswireBRISBANE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients
- 1y agoVERAVera Therapeutics to Participate in the TD Cowen Immunology & Inflammation SummitGlobeNewswireBRISBANE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients
- 1y agoVERAVera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA NephropathyGlobeNewswireAtacicept received FDA Breakthrough Therapy Designation for the treatment of IgANORIGIN Phase 3 trial met its primary endpoint at the prespecified interim analysis of proteinuria reduction with 46% reduction from
- 1y agoVERAVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBRISBANE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that, on November 4, 2025, the Compensation Committee of the Board of Directors of Vera Therapeutics granted
- 1y agoVERAVera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of MedicineGlobeNewswireAtacicept met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared to placebo at week 36 (p<0.0001)The
- 1y agoVERAVera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial ResultsGlobeNewswireORIGIN 3 trial primary endpoint results for Atacicept in IgA nephropathy (IgAN) selected as a featured late-breaking oral presentation during opening plenary session of American Society of Nephrology (ASN) Kidney Week
- 1y agoVERAVera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ETGlobeNewswireBRISBANE, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients